Your SlideShare is downloading. ×
3 Humongous Healthcare Stocks This Week   2-28-14
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

3 Humongous Healthcare Stocks This Week 2-28-14

5,687
views

Published on

The best-performing healthcare stocks over the last week.

The best-performing healthcare stocks over the last week.

Published in: Health & Medicine

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
5,687
On Slideshare
0
From Embeds
0
Number of Embeds
10
Actions
Shares
0
Downloads
7
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849
  • Transcript

    • 1. 3 Humongous Health-Care Stocks This Week
    • 2. While winter is definitely still here for most of the U.S., some health-care stocks are already generating a lot of heat. Here are the three most humongous health-care stocks of the past week. Source: Wikimedia Commons/
    • 3. InterMune (Nasdaq: ITMN) Shares of the biotech soared 118% this week.
    • 4. Why Intermune more than doubled • It announced phase 3 data for Esbriet. • The drug significantly reduced progression of idiopathic pulmonary fibrosis in patients. • InterMune plans to resubmit the New Drug Application for Esbriet by Q3 of this year.
    • 5. Celladon (Nasdaq: CLDN) Shares of the biotech focusing on cardiovascular disease drugs jumped more than 49% this week.
    • 6. Why Celladon took off • It announced that French drugmaker Servier optioned its novel SERCA2b modulators for treating type 2 diabetes and other metabolic diseases. • Servier gets exclusive global rights outside the U.S. • Celladon also benefited from two analysts initiating coverage this week -- Barclays with an “overweight” rating and Stifel with a “buy” rating.
    • 7. Prana Biotechnology (Nasdaq: PRAN) Shares of the biopharmaceutical company surged nearly 41% higher for the week.
    • 8. Why Prana pushed higher • Investment firm H.C. Wainwright upped its price target for Prana from $20.50 to $33 per share. • The stock experienced a rebound after a big sell-off two weeks ago. • That sell-off stemmed from Summer Street’s doubts about data for Prana’s PBT2, which targets treatment of Huntington’s and Alzheimer’s diseases.
    • 9. Best pick to stay humongous? • Any or all of this week’s humongous stocks could keep moving up. • Celladon gets the nod for most likely to continue its winning ways. • The Servier deal is a huge vote of confidence for the biotech, which only recently went public. • Positive endorsements from major analysts should keep big money flowing into this stock.
    • 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!